Greenleaf Trust Sells 41,316 Shares of Pfizer Inc. (NYSE:PFE)

Greenleaf Trust reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 266,290 shares of the biopharmaceutical company’s stock after selling 41,316 shares during the quarter. Greenleaf Trust’s holdings in Pfizer were worth $7,666,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Worth Asset Management LLC purchased a new position in shares of Pfizer in the 1st quarter worth $29,000. Briaud Financial Planning Inc bought a new stake in shares of Pfizer during the 3rd quarter valued at about $30,000. Sanctuary Wealth Management L.L.C. purchased a new stake in shares of Pfizer during the 4th quarter valued at about $50,000. Mizuho Securities Co. Ltd. bought a new stake in Pfizer during the third quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on PFE. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.60 during trading hours on Friday, reaching $25.99. The company’s stock had a trading volume of 38,347,117 shares, compared to its average volume of 42,429,016. The firm has a 50 day moving average price of $27.14 and a 200-day moving average price of $28.74. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market cap of $147.17 billion, a P/E ratio of 72.22, a P/E/G ratio of 1.15 and a beta of 0.61. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.14 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.